Company Overview

Vanda Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) and rare disorders. The company operates within the biopharmaceutical and specialty pharmaceuticals industries, with a strategic emphasis on neuroscience, sleep disorders, and movement disorders. Its revenue is primarily driven by the commercialization of proprietary drugs and related collaborations.

Vanda’s marketed products include Hetlioz (tasimelteon), approved for non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome, and Fanapt (iloperidone), an antipsychotic for schizophrenia. The company differentiates itself through a focused CNS portfolio, long-term development of circadian rhythm therapies, and ownership of global commercialization rights for key products. Founded in 2002, Vanda evolved from a development-stage biotech into a commercial-stage pharmaceutical company following the FDA approval of Hetlioz in 2014.

Business Operations

Vanda operates as a single-reportable-segment biopharmaceutical company, generating revenue primarily from product sales of Hetlioz and Fanapt, as well as royalty and milestone income from select partnerships. The company manages clinical development, regulatory strategy, manufacturing oversight (via third-party manufacturers), and commercialization, including sales and medical affairs functions.

Operations are concentrated in the United States, which represents the majority of revenue, while international sales are conducted through distributors and partners in Europe, Asia-Pacific, and other regions. Vanda controls its core intellectual property portfolio and maintains full or partial commercial rights to its products in major markets. The company has historically engaged in selective licensing and collaboration arrangements but remains largely vertically integrated in its commercial activities.

Strategic Position & Investments

Vanda’s strategy centers on maximizing the lifecycle value of its approved products while advancing a pipeline of CNS-focused drug candidates. Growth initiatives include label expansions for Hetlioz, post-marketing studies, and late-stage development programs targeting movement disorders, bipolar disorder, and other neuropsychiatric indications. The company emphasizes internal R&D over large-scale acquisitions.

Investments are primarily directed toward clinical trials, regulatory submissions, and patent defense related to its core products. Vanda has evaluated and, at times, pursued strategic transactions, including acquisitions or licensing opportunities, but public sources indicate no transformative acquisitions completed in recent years. The company has also explored emerging applications of circadian biology and personalized medicine within sleep and neurological disorders.

Geographic Footprint

Vanda is headquartered in Washington, D.C., United States, which serves as its primary center for corporate, regulatory, and commercial operations. The U.S. market accounts for the majority of product sales, supported by a domestic sales force and distribution network.

Internationally, Vanda maintains a commercial and operational presence across Europe, Canada, Japan, and parts of Asia-Pacific through subsidiaries, licensees, and distribution partners. While the company does not operate large manufacturing facilities globally, its international footprint provides access to key regulated pharmaceutical markets and supports long-term expansion of its CNS portfolio.

Leadership & Governance

Vanda was founded by Mihael H. Polymeropoulos, whose scientific background shaped the company’s long-standing focus on neuroscience and circadian rhythm disorders. The leadership team emphasizes disciplined capital allocation, data-driven clinical development, and long-term product ownership as core elements of its strategic vision.

Key executives include:

• Mihael H. Polymeropoulos – Founder, President, and Chief Executive Officer
• Kevin Moran – Chief Financial Officer
• Anastasia Ivleva – Senior Vice President, General Counsel
• Michael O’Keeffe – Senior Vice President, Commercial Operations
• Nicholas Panagopoulos – Senior Vice President, Technical Operations

The board and executive leadership maintain a governance framework aligned with U.S. public company standards, with oversight of clinical risk, regulatory compliance, and intellectual property strategy.